May 15, 2020
Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Apr 28, 2020
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
Apr 22, 2020
CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
Jan 17, 2020
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines Corporation to Distribute AYVAKIT(TM) (avapritinib) for Genomically Defined Patient Population with Rare Cancer, GIST
Jan 13, 2020
Blueprint Medicines Announces 2020 Corporate Goals
Jan 09, 2020
Blueprint Medicines Announces FDA Approval of AYVAKIT(TM) (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
Dec 10, 2019
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST
Oct 28, 2019
Blueprint Medicines Announces FDA Intent to Split Avapritinib New Drug Application into Separate Submissions for PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Aug 26, 2019
CStone announces first patient dosed in China for Phase I/II registrational bridging trial of avapritinib in advanced GIST
Aug 07, 2019
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jul 09, 2019
CStone announces first patient dosed in China with avapritinib in global Phase III clinical trial in advanced GIST
Jun 14, 2019
Blueprint Medicines Submits New Drug Application to U.S. Food and Drug Administration for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
Jun 01, 2019
Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib
Apr 25, 2019
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market
Apr 15, 2019
CStone received IND approval in China for avapritinib Phase I/II bridging registrational study in patients with advanced gastrointestinal stromal tumors
Mar 27, 2019
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress
Feb 26, 2019
Blueprint Medicines Reports Fourth Quarter and Full Year 2018 Financial Results
Jan 18, 2019
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
Jun 21, 2018
Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors
Nov 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRa Genotypes